

CURRICULUM VITAE

NAME:

Terrence F. Blaschke, M.D.

WORK:

Stanford: Division of Clinical Pharmacology
Room S-009
Stanford University Medical Center
Stanford, CA 94305-5130

EDUCATION:

1960 - 1964 B.S., University of Denver, Denver, Colorado; Honors Program, Major Subject: Mathematics (Cum Laude).

1964 - 1968 M.D., Columbia University College of Physicians and Surgeons, New York, New York

CLINICAL TRAINING:

1968 - 1969 Intern in Medicine, University of California Center for Health Sciences, Los Angeles, California

1969 - 1970 Assistant Resident in Medicine, University of Calif. Center for Health Sciences, Los Angeles, CA

1970 - 1972 Clinical Associate, Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

1972 - 1974 Clinical Fellow, Division of Clinical Pharmacology, Department of Medicine, University of California, San Francisco Medical Center, San Francisco, CA

RESEARCH TRAINING:

1965 (Summer)	Medical Student Summer experience, Department of Pathology, University of Colorado Medical Center, Denver, Colorado
1970 – 1972	Clinical Associate, Metabolism Branch, NCI, NIH
1972 – 1974	Research Fellow, Division of Clinical Pharmacology, University of California, San Francisco Medical Center
1980 – 1981	Visiting Worker, Division of Molecular Pharmacology, National Institute for Medical Research, London, England
1990 (6 mos.)	Visiting Worker, Center for Biopharmaceutical Sciences, University of Leiden, and Department of Medical Information Sciences, Erasmus University, The Netherlands.

POSITIONS:

1974 – 1981	Assistant Professor of Medicine (Clinical Pharmacology) Stanford University School of Medicine, Stanford, CA
1978 –	Chief, Division of Clinical Pharmacology
1978 – 1981	Assistant Professor of Pharmacology, Stanford University School of Medicine, Stanford, CA
1981 – 1991	Associate Professor of Medicine (Clinical Pharmacology) and Pharmacology, Stanford University School of Medicine
1991 –	Professor of Medicine (Clinical Pharmacology) and Molecular Pharmacology, Stanford University School of Medicine (Currently on Leave of Absence)
1997	Visiting Faculty, Moi University School of Medicine, Eldoret, Kenya (2 mos)
1997 – 1998	Visiting Professor, Georgetown University Center for Drug Development Science, and Special Government Employee, OCPB/FDA/CDER (November 1997 - March 1998, 5 mos.)
2000 – 2002	Vice President, Methodology and Science, Pharsight Corporation, Mountain View, CA
2001 –	Adjunct Professor, Department of Biopharmaceutical Sciences, School of Pharmacy, University of California, San Francisco
2002 –	Associate Dean for Medical Student Advising, Stanford University

CERTIFICATION AND LICENSURE:

1969	Diplomate, National Board of Medical Examiners
1972	Medical License, State of California
1973	Diplomate, American Board of Internal Medicine
1991	Diplomate, American Board of Clinical Pharmacology (Charter Member)

MILITARY SERVICE:

1970 –1972 Commissioned Officer, United States Public Health Service

AWARDS; HONORS:

Recipient, Pharmaceutical Manufacturers Association Foundation Faculty Development Award in Clinical Pharmacology
Recipient, Burroughs-Wellcome Scholar Award in Clinical Pharmacology
Recipient, RCDA from NIGMS 1978 - 1983
Stanford University School of Medicine Henry J. Kaiser Award for Outstanding Contributions to Medical Education – 1999
Recipient, Rawls-Palmer Progress in Medicine Lecture and Award of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) – 2002

SOCIETIES; PROFESSIONAL ACTIVITIES:

American Society for Clinical Pharmacology and Therapeutics (ASCPT)
 President (1988-1989)
 Associate Secretary-Treasurer (1990 - 1992)
 Chairman, ASCPT Liaison Committee for Clinical Pharmacology (1985 - 1989)
 Chairman, Scientific Program Committee (1986 - 1987)
 Chairman, Long Range Planning Committee (1992 - 1994)
 Chairman, Scientific Awards Committee (1997 - 2000)
American Society of Pharmacology and Experimental Therapeutics
 Member, Executive Committee of the Clinical Pharmacology Division (1986-1989)
 Chair-elect, Clinical Pharmacology Division (2002-2003)
American Board of Clinical Pharmacology, Board of Governors (1990-1992)
American Federation for Clinical Research
Western Society for Clinical Investigation
Western Association of Physicians
Western Pharmacology Society
American Association for the Advancement of Science
Georgetown University Center for Drug Development Science, Scientific Advisory Board Member

EDITORIAL BOARDS AND STUDY SECTIONS:

Journals, Books, Websites:

Associate Editor, Annual Review of Pharmacology and Toxicology (1989 –)
Editorial Board, Clinical Pharmacology and Therapeutics (1981 –)
Editorial Board, Drug Metabolism and Disposition (1994 – 2000)
Editorial Board, Drug Therapeutics: Concepts for Physicians (1978 – 1981)
Editorial Board, Rational Drug Therapy (1984 –1985)
Editorial Board, Drug Interaction Facts (1983 – 1987)
Editorial Board, <http://www.hivpharmacology.com/> (2001 –)

Study Sections:

Member, Pharmacology Study Section, DRG, National Institutes of Health (1979 – 1983)
Member, VA Merit Review Board for Clinical Pharmacology, Alcohol & Drug Dependence (1984 – 1986)
Member, California Heart Association Northern Peer Review Subcommittee (1978 – 1979)

COMMITTEES:

State:

State of California Department of Health Services
Medi-Cal Drug Use Review Board (1993 – 1997)

National:

AIDS Clinical Trials Group (ACTG) Program, NIAID, NIH
Chairman, Pharmacology Committee, (1990 – 1992)
Executive Committee, (1993 – 1997)
United States Pharmacopeia
1995-2000 USP Committee of Revision; Chair, Panel on Drug Utilization Review
Food and Drug Administration
Generic Drugs Advisory Committee, Chair, (1990 – 1994)
Search Committee, Director, Center for Drug Evaluation and Research, 1993
Expert Consultant, Division of Biopharmaceutics, (1976 – 1980)
Special Government Employee, OCPB/FDA/CDER (Nov 1997 – Present)
Merck Foundation
Member, Selection Committee, Merck Sharp and Dohme International Fellowships in Clinical Pharmacology (1990 – 1994)
Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation
Member, Clinical Pharmacology Advisory Committee
Merck Sharp and Dohme Research Laboratories, Rahway NJ
Member, Board of Scientific Advisors (Human Health)(1986 – 1990)
American College of Physicians
Chairman, Clinical Pharmacology Section, MKSAP VIII
Federation of State Medical Boards and the National Board of Medical Examiners
Member, USMLE Step 3 Computer-based Case Simulation Test Material Development Committee

Stanford Committees/Activities

Course Director, Preparation for Clinical Medicine (Part C, Clinical Reasoning)(1992 – 2000)

Department of Medicine Committee on the Voluntary Clinical Faculty (Co-Chair)
Associate Director, Stanford University School of Medicine General Clinical Research Center
SUH Quality Assurance Control Committee
SUH Health Promotion Advisory Board
SUH Pharmacy and Therapeutics Committee (Chair)
Medical School Computing Committee
Physicians Implementation Committee
University Faculty Senate
School of Medicine Committee on Courses and Curriculum
Stanford University Subcommittee on the Evaluation and Improvement of Teaching (S-CEIT)
General Clinical Research Center Advisory Committee (Chairman, 1987 – 1990)
Center for AIDS Research (CFAR), Senior Member
Center for Advanced Medical Information Sciences (CAMIS), Executive Committee
Department of Medicine Appointments and Promotions Committee

PRESENT RESEARCH INTERESTS:

My ongoing Stanford research activities involve studies on the clinical pharmacology of drugs used in HIV-infected patients.

A focus of my laboratory's efforts in investigating drugs used in HIV-infected patients is to optimize the individual benefit/risk of pharmacotherapy of HIV or opportunistic infections by discovering and quantifying the pharmacokinetics and pharmacodynamics (PK/PD) of drugs used in such therapy; i.e., the distribution of individual-specific dose-concentration-effect relationships in the population. My laboratory has a special interest in understanding the relationships between antiviral drug exposure and virologic and toxicological responses. For the past several years, this has lead to studies examining drug-taking behavior in these patients, since exposure is made up of both individual variation in pharmacokinetics and individual patterns of drug-taking behavior. The broader goal is to carry out kinetic/dynamic modeling (PK/PD modeling) to understand the determinants of drug response..

In the area of cardiovascular pharmacology, my laboratory has been involved, in collaboration with Professor Brian Hoffman, in examining the action of various drugs and endogenous compounds on vascular smooth muscle. Many of the studies measured smooth muscle reactivity using veins on the back of the hand of human subjects. Signal transduction pathways, tolerance, and the effects of smoking, age and diseases on vascular function have been of particular interest.

**APPEARS THIS WAY
ON ORIGINAL**

BIBLIOGRAPHY

ORIGINAL ARTICLES:

1. Berk PD, Bloomer JR, Howe RB, Blaschke TF, and Berlin NI: Bilirubin production as a measure of red cell life span. JOURNAL OF LABORATORY AND CLINICAL MEDICINE 79:364-378, 1972.
2. Berk PD, Blaschke TF, and Waggoner JG: Defective BSP clearance in patients with constitutional hepatic dysfunction (Gilbert's Syndrome). GASTROENTEROLOGY 63:472-481, 1972.
3. Berk PD and Blaschke TF: Detection of Gilbert's Syndrome in patients with hemolysis, using radioactive chromium. ANNALS OF INTERNAL MEDICINE 77:527-531, 1972.
4. Blaschke TF and Berk PD: Augmentation of bilirubin-UDP-glucuronyl transferase activity in rat liver homogenates by glutethimide. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 140:315-318, 1972
5. Blaschke TF, Elin RJ, Berk PD, Song CS and Wolff SM: The effect of induced fever on sulfobromophthalein kinetics in man. ANNALS OF INTERNAL MEDICINE 78:221-226, 1973.
6. Berk PD, Rodkey FL, Blaschke TF, Collison HA and Waggoner JG: Comparison of plasma bilirubin turnover and carbon monoxide production in man. JOURNAL OF LABORATORY AND CLINICAL MEDICINE 83:29-37, 1974.
7. Blaschke TF, Berk PD, Rodkey FL, Scharschmidt BF, Collison HA and Waggoner JG: Drugs and the liver: 1. Effects of glutethimide and phenobarbital on hepatic bilirubin clearance, plasma bilirubin turnover and carbon monoxide production in man. BIOCHEMICAL PHARMACOLOGY 23:2795-2806, 1974.
8. Blaschke TF, Berk PD, Scharschmidt BF, Guyther JR, Vergalla JM and Waggoner JG: Crigler-Najjar Syndrome: an unusual course with development of neurologic damage at age 18. PEDIATRIC RESEARCH 8:573-590, 1974.
9. Berk PD, Scharschmidt BF and Blaschke TF: Hepatic bilirubin clearance (CBR) in the differential diagnosis of unconjugated hyperbilirubinemia. 1. Estimation of CBR from studies with radiochromium. EPATOLOGIA 20:245-256, 1974.
10. Blaschke TF, Meffin PJ, Melmon KL and Rowland M: Influence of acute viral hepatitis on phenytoin kinetics and protein binding. CLINICAL PHARMACOLOGY AND THERAPEUTICS 17:685-691, 1975.
11. Patterson JR, Blaschke TF, Hunt KK and Meffin PJ: Lidocaine blood concentration during fiberoptic bronchoscopy. AMERICAN REVIEW OF RESPIRATORY DISEASES 112:53-57, 1975.
12. Martin JF, Mikulecky M, Blaschke TF, Waggoner JG, Vergalla J and Berk PD: Differences between the plasma indocyanine green disappearance rates of normal men and women. PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 150:612-617, 1975.
13. Berk PD, Blaschke TF, Scharschmidt BF, Waggoner JG and Berlin, NI: A new approach to quantitation of the various sources of bilirubin in man. JOURNAL OF LABORATORY AND CLINICAL MEDICINE 87:767-780, 1976.
14. Williams RL, Schary WL, Blaschke TF, Meffin PJ, Melmon KL and Rowland M: Influence of acute viral hepatitis on the disposition and pharmacologic effect of warfarin. CLINICAL PHARMACOLOGY AND THERAPEUTICS 20:997,1976.

15. Williams RL, Blaschke TF, Meffin PJ, Melmon KL and Rowland M: Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine green. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 20:290-299, 1976.
16. Meffin PJ, Williams RL, Blaschke TF and Rowland M: Application of salivary concentration data to pharmacokinetic studies with antipyrine. *JOURNAL OF PHARMACEUTICAL SCIENCES* 66:135-137, 1977.
17. Bjornsson TD, Blaschke TF and Meffin PJ: High pressure liquid chromatographic analysis of drugs in biological fluids. II. Determination of warfarin. *JOURNAL OF PHARMACEUTICAL SCIENCES* 66:142-144, 1977.
18. Williams RL, Blaschke TF, Meffin PJ, Melmon KL and Rowland M: Influence of acute viral hepatitis on the disposition and plasma binding of tolbutamide. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 21:301-309, 1977.
19. Meffin PJ, Winkle RA, Blaschke TF, Fitzgerald JW and Harrison DC: Response optimization of drug dosage: antiarrhythmic studies with tocainide. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 22:42-57, 1977.
20. Bjornsson TD, Meffin PJ and Blaschke TF: Interaction of clofibrate with warfarin. I. The effects of clofibrate on the disposition of the optical enantiomorphs of warfarin. *JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS* 5:495-505, 1977.
21. Bjornsson TD, Blaschke TF and Meffin PJ: High pressure liquid analysis of drugs in biological fluids. IV. Determination of clofibrinic acid. *JOURNAL OF CHROMATOGRAPHY* 137:145-152, 1977.
22. Bjornsson TD, Swezey SE, Meffin PJ and Blaschke TF: Quantitation of radiolabelled vitamin K1 and vitamin K1 epoxide in plasma by high pressure liquid chromatography. *THROMBOSIS AND HEMOSTASIS* 39:466-473, 1978.
23. Swezey SE, Blaschke TF and Meffin PJ: Gas chromatographic analysis of pentazocine. *JOURNAL OF CHROMATOGRAPHY* 154:256-260, 1978.
24. Ramu A, Rosenbaum J and Blaschke TF: Disposition of acetone following acute acetone intoxication. *WESTERN JOURNAL OF MEDICINE* 129:429-432, 1978.
25. Ramu A, Glaubiger D, Ramu NP, Eldridge N and Blaschke TF: Probenecid inhibition of methotrexate excretion from cerebrospinal fluid in dogs. *JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS* 6:389-397, 1978.
26. Esquivel M, Blaschke TF, Snidow G and Meffin PJ: Effect of phenobarbitone on the disposition of lignocaine and warfarin in the dog. *JOURNAL OF PHARMACY AND PHARMACOLOGY* 30:804-805, 1978.
27. Bjornsson TD and Blaschke TF: Vitamin K1 disposition and therapy of warfarin overdose. *LANCET* 3:846-847, 1978.
28. Ramu A, Fusner JE, Blaschke TF and Glaubiger DL: Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs. *CANCER TREATMENT REPORTS* 62:1465-1470, 1978.
29. Neal EA, Meffin PJ, Gregory PB and Blaschke TF: Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis. *GASTROENTEROLOGY* 77:96-102, 1979.
30. Yee G, Rubin PC and Blaschke TF: Atenolol determination by high pressure liquid chromatography and fluorescence detection. *JOURNAL OF CHROMATOGRAPHY*

171:357-362, 1979.

31. Jaillon P, Rubin PC, Yee Y-G, Ball R, Kates R, Harrison DC and Blaschke TF: Influence of congestive heart failure on prazosin pharmacokinetics. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 25:790-794, 1979.
32. Rubin PC and Blaschke TF: Plasma catecholamines in man are not influenced by the inhibition of prostaglandin synthesis. *PROSTAGLANDIN* 17:581-585, 1979.
33. Swezey SE, Meffin PJ and Blaschke TF: Measurement of furosemide by high pressure liquid chromatography. *JOURNAL OF CHROMATOGRAPHY* 174:469-473, 1979.
34. Bjornsson TD, Meffin PJ, Swezey SE and Blaschke TF: Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. *JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS* 210:316-321, 1979.
35. Bjornsson TD, Meffin PJ, Swezey SE and Blaschke TF: Effects of clofibrate and warfarin alone and in combination on the disposition of vitamin K1. *JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS* 210:322-326, 1979.
36. Rubin P, Yee Y-G, Anderson M and Blaschke TF: Prazosin first-pass metabolism and hepatic extraction in the dog. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 1:641-647, 1979.
37. Rubin P, Swezey S and Blaschke TF: Naloxone lowers plasma prolactin in man. *LANCET* 1:1293, 1979.
38. Rubin P. and Blaschke TF: Prazosin protein binding in health and disease. *BRITISH JOURNAL OF CLINICAL PHARMACOLOGY* 9:177-182, 1980.
39. Bjornsson TD, Meffin PJ, Peters FA and Blaschke TF: Saliva and plasma concentrations and plasma protein binding of clofibrinic acid in uremic patients. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 27:230-235, 1980.
40. Giacomini KM, Swezey SE, Giacomini JC and Blaschke TF: Administration of heparin causes in vitro release of non-esterified fatty acids in human plasma. *LIFE SCIENCES* 27:771-780, 1980.
41. Rubin PC and Blaschke TF: Studies on the clinical pharmacology of prazosin. I. Cardiovascular, catecholamine and endocrine changes following a single dose. *BRITISH JOURNAL OF CLINICAL PHARMACOLOGY* 10:23-32, 1980.
42. Rubin PC, Jackson G and Blaschke TF: Studies on the clinical pharmacology of prazosin. II. The influence of indomethacin and of propranolol on the action and disposition of prazosin. *BRITISH JOURNAL OF CLINICAL PHARMACOLOGY* 10:33-39, 1980.
43. Giacomini KM, Giacomini JC, Swezey SE, Harrison DC, Nelson WL, Burke TR and Blaschke TF: The stereoselective disposition of disopyramide in the dog. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 2:825-832, 1980.
44. Giacomini KM, Cox BM and Blaschke TF: Comparative anti-cholinergic potencies of R- and S- disopyramide in longitudinal muscle strips from guinea pig ileum. *LIFE SCIENCES* 27:1191-1197, 1980.
45. Vreman HJ, Assomull VM, Kaiser BA, Blaschke TF and Weiner MW: Acetate metabolism and acid-base homeostasis during hemo-dialysis: influence of dialyzer efficiency and metabolic capacity for acetate metabolism. *KIDNEY INTERNATIONAL* 18 (Suppl 10):S62-S74, 1980.
46. Giacomini KM, Giacomini JC and Blaschke TF: Absence of effect of heparin on the binding of prazosin and phenytoin to plasma proteins. *BIOCHEMICAL*

PHARMACOLOGY 29:3337-3340, 1980.

47. Rubin P, Blaschke TF and Guillemainault C: Effect of naloxone -a specific opioid inhibitor on blood pressure fall during sleep. CIRCULATION 63:117-121, 1981.
48. Nelson WL, Sneed CK, Giacomini KM, Giacomini JC, Strauss J, Blaschke TF and Cox BM: Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of the disopyramide. JOURNAL OF MEDICINAL CHEMISTRY 24:614-617, 1981.
49. Carlisle DC and Blaschke TF: Vitamin K1, Vitamin K1 epoxide and warfarin interrelationships in the dog. BIOCHEMICAL PHARMACOLOGY 30:2931-2936, 1981.
50. Sawhney VK, Gregory PB, Swezey SE and Blaschke TF: Furosemide disposition in cirrhotic patients. GASTROENTEROLOGY 81:1012-1016, 1981.
51. Giacomini KM, Swezey SE, Turner-Tamiasu K and Blaschke TF: The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 10:1-14, 1982.
52. Pollick C, Giacomini KM, Blaschke TF, Nelson WL, Turner-Tamiasu K, Briskin VH and Popp RL: The cardiac effects of d-and l-disopyramide on normal subjects. A non-invasive study. CIRCULATION 66(2):447-453, 1982.
53. Swezey SE, Giacomini KM, Abang A, Brass C, Stevens DA and Blaschke TF: Measurement of ketoconazole, a new antifungal agent, by high performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY 227:510-515, 1982.
54. Smith GA, Schulz P, Giacomini KM, and Blaschke TF: High pressure liquid chromatographic determination of amitriptyline and its major metabolites in human whole blood. JOURNAL OF PHARMACEUTICAL SCIENCES 71:581-583, 1982.
55. Brass C, Galgiani JN, Defelice R, Blaschke TF, O'Reilly RA and Stevens DA: Disposition of ketoconazole, an oral antifungal, in man. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 21:151-158, 1982.
56. Richards RH, Vreman HJ, Zager P, Feldman C, Blaschke T and Weiner MW: Acetate metabolism in normal human subjects. AMERICAN JOURNAL OF KIDNEY DISEASES 2(1):47-57, 1982.
57. Schulz P, Reaven GM and Blaschke TF: Growth hormone release after acute amitriptyline administration to normal human subjects. PSYCHOPHARMACOLOGY 76:299-301, 1982.
58. Giacomini KM, Abang A and Blaschke TF: Calculation of drug concentration in plasma after equilibrium dialysis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 14:752-754, 1982.
59. Schulz P, Turner-Tamiasu K, Smith G, Giacomini KM and Blaschke TF: Disposition of amitriptyline in young and elderly normal males. CLINICAL PHARMACOLOGY AND THERAPEUTICS 33:360-366, 1983.
60. Schulz P, Giacomini KM, Luttrell S, Turner-Tamiasu K and Blaschke TF: Effect of low doses of heparin on plasma binding of phenytoin and prazosin in normal humans. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 25:211-214, 1983.
61. Schulz P, Abang A, Giacomini JC, Blaschke TF and Giacomini KM: Effect of heparin on the red blood cell-to-plasma concentration ratio of diphenylhydantoin and prazosin. THERAPEUTIC DRUG MONITORING 5:497-499, 1983.
62. Schulz P and Blaschke TF: The pharmacokinetic interaction of single doses of quinine and digoxin in dogs. PHARMACOLOGY 28:343-346, 1984.

63. Smith GA, Giacomini KM, Smith CT, Gregory PB, Robinson WE, Merigan TC and Blaschke TF: High-performance liquid chromatographic analysis of hypoxanthine arabinoside in plasma. JOURNAL OF CHROMATOGRAPHY (Biomedical Applications) 307:410-415, 1984.
64. Witkowska MK and Blaschke TF: Dexamethasone decreases plasma protein binding of prazosin in vivo in rabbits. (Short Communication) CLINICAL PHARMACOKINETICS 9(Suppl. 1):100-101, 1984.
65. Taylor G and Blaschke TF: Measurement of antipyrine half-life from urinary drug concentrations. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 18:650-652, 1984.
66. Taylor G, Marafino BJ, Moore JA, Gurley VA and Blaschke TF: Interferon reduces hepatic drug metabolism in vivo in mice. DRUG METABOLISM AND DISPOSITION 13:459-463, 1985.
67. Giacomini JC, Giacomini KM, Nelson WL, Harrison DC and Blaschke TF: Electro-physiology of the enantiomers of disopyramide in dogs. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 7:884-890, 1985.
68. McEwen JG, Peters GR, Blaschke TF, Brummer E, Perlman AM, Restrepo A and Stevens DA: Therapy of paracoccidioidomycosis with itraconazole in a murine model. JOURNAL OF TROPICAL MEDICINE AND HYGIENE 88:295-299, 1985.
69. Anderson JE and Blaschke TF: Ketoconazole inhibits cyclosporine metabolism in vivo in mice. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 236:671-674, 1986.
70. Giacomini KI, Nelson WL, Pershe RA, Valdivieso L, Turner-Tamiasu K and Blaschke TF: In Vivo interaction of the enantiomers of disopyramide in human subjects. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 14:335-356, 1986
71. Speedie SM, Skarupa S, Oderda L, Blaschke TF, Leatherman E, Kondo J, Gray J, Olson W: MENTOR: Continuously monitoring drug therapy with an expert system. MEDINFO 86 (Proceeding of the Fifth Conference on Medical Informatics) (R Salamon, B. Blum, M Jorgensen, editors) Elsevier Science Publishers, B.V. (North Holland), 1986, pp 237-239.
72. Anderson JE, Morris RE, Blaschke TF: Pharmacodynamics of cyclosporine-ketoconazole interaction in mice: combined therapy potentiates cyclosporine immunosuppression and toxicity. TRANSPLANTATION 43:529-533, 1987.
73. Pan HY-M, Hoffman BB, Pershe RA, and Blaschke TF: Decline in beta-adrenergic receptor-mediated vascular relaxation with aging in man. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 239:802-807, 1987.
74. Valdivieso L, Giacomini KM, Nelson WL, Pershe RA and Blaschke TF: Stereoselective binding of disopyramide to plasma proteins. PHARMACEUTICAL RESEARCH 5:316-318, 1988.
75. Atiba JO and Blaschke TF: Etomidate inhibits antipyrine metabolism in mice. AMERICAN JOURNAL OF MEDICAL SCIENCES 293:361-365, 1987.
76. Atiba JO, Taylor G, Pershe RA and Blaschke TF: Plasma antipyrine half-life can be determined from urine data. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 23:715-719, 1987.
77. Garfinkel D, Mamelok RD and Blaschke TF: Altered therapeutic range for quinidine following myocardial infarction and cardiac surgery. ANNALS OF INTERNAL MEDICINE 107:48-50, 1987.

78. Eichler HG, Hiremath A, Katzir D, Blaschke TF and Hoffman BB: Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in man. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 42:521-524, 1987.
79. Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke TF, Howes AE, Wasserman TH, Urtasun RC, Pajik T, Hancock S, Phillips TL, Noll L: Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR2508 and the pharmacokinetic profile. *CANCER RESEARCH* 47:319-322, 1987.
80. Speedie SM, Skarupa S, Blaschke TF, Kondo J, Leatherman RE, Perreault L: MENTOR: integration of an expert system with a hospital information system. Proceedings of the Eleventh Annual Symposium on Computer Applications in Medical Care (Stead, W. W., ed.) [Nov. 1-4, 1987, Washington, D.C.] Computer Society Press, Los Angeles, 1987, pp. 220-224.
81. Atiba JO, Horai Y, White PF, Trevor AJ, Blaschke TF, Sung M-L: Effect of etomidate on hepatic drug metabolism in humans. *ANESTHESIOLOGY* 68:920-924, 1988.
82. Eichler HG, Blaschke TF, Hoffman BB: Decreased responsiveness of superficial hand veins to phenylephrine in black normotensive males. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 16:177-181, 1990.
83. Hiremath AN, Pershe RA, Hoffman BB, Blaschke TF: Comparison of age-related changes in prostaglandin E₁ and beta-adrenergic responsiveness of vascular smooth muscle in man. *JOURNAL OF GERONTOLOGY: MEDICAL SCIENCES* 41:M13-M17, 1989.
84. Eichler HG, Eichler I, Lewiston N, Blaschke TF, Hoffman BB: Responsiveness of superficial hand veins to adrenergic stimuli in patients with cystic fibrosis. *CLINICAL SCIENCE* 76:283-287, 1989.
85. La Delfa I, Zhu Q-M, Mo Z, Blaschke TF: Fluconazole is a potent inhibitor of antipyrine metabolism in vivo in mice. *DRUG METABOLISM AND DISPOSITION* 17:49-53, 1989.
86. Ford GA, Eichler HG, Hoffman BB, Blaschke TF: Venous responsiveness to atrial natriuretic factor in man. *BRITISH JOURNAL OF CLINICAL PHARMACOLOGY* 26:797-799, 1988.
87. Eichler HG, Ford GA, Blaschke TF, Swislocki A, Hoffman BB: Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy. *JOURNAL OF CLINICAL INVESTIGATION* 83:108-112, 1989.
88. Hiremath AN, Hoffman BB, Blaschke TF: Responsiveness of peripheral veins to transdermal and sublingual nitroglycerin in man. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 14:534-541, 1989.
89. Ferguson JE, Schutz T, Pershe R, Stevenson DK, Blaschke TF: Nifedipine pharmacokinetics during preterm labor tocolysis. *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY* 161:1485-1490, 1989.
- 90a. Lenert LA, Sheiner LB, Blaschke TF: Improving drug dosing in hospitalized patients: automated modeling of pharmacokinetics for individualization of drug dosage regimens. *COMPUTER PROGRAMS IN BIOMEDICINE* 30:169-176, 1989.
- 90b. Lenert L, Sheiner L, Blaschke T: Improving drug dosing in hospitalized patients: automated modeling of pharmacokinetics for individualization of drug dosage regimens. *PROCEEDINGS - SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICAL CARE* (Greenes RA ed.), Institute of Electrical and Electronics Engineers, New York, 1988, pp. 308-312.
91. Torseth J, Bhatia G, Harkonen S, Child C, Skinner M, Robinson WS, Blaschke TF, Merigan TC: Evaluation of the antiviral effect of rifabutin in AIDS-related complex. *JOURNAL OF*

INFECTIOUS DISEASE 159:1115-1118, 1989.

92. De Blik R, Friedman CP, Blaschke TF, France C, Speedie SM: Practitioner preferences and receptivity for patient-specific advice from a therapeutic monitoring system. PROCEEDINGS - SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICAL CARE (Greenes RA ed.), Institute of Electrical and Electronics Engineers, New York, 1988, pp. 225-228.
93. Speedie SM, Skarupa S, Blaschke TF, Kondo J, Leatherman E, Friedman C, de Blik R: An expert system for monitoring drug therapy using data acquired from an HIS: The MENTOR System. DEMONSTRATIONS DIGEST - SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICAL CARE (Greenes RA ed.), Institute of Electrical and Electronics Engineers, New York, 1988, pp 27-29.
94. Skinner MH, Lenert L, Blaschke TF: Theophylline toxicity subsequent to ranitidine administration: a possible drug-drug interaction. AMERICAN JOURNAL OF MEDICINE 86:129-132, 1989
95. Kearns PJ, Young HS, Garcia G, Blaschke TF, O'Hanlon G, Rinki M, Sucher K, Gregory PB: Accelerated improvement of alcoholic liver disease with enteral nutrition. GASTROENTEROLOGY 102:200-205, 1992.
96. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, Blaschke TF: Pharmacokinetics of Rifabutin. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 33:1237-1241, 1989.
97. Atiba JO, Blaschke TF, Wilkinson GR: Effects of ketoconazole on the polymorphic 4-hydroxylation of s-mephenytoin and debrisoquine. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 28:161-165, 1989.
98. La Delfa I, Xia Y, Blaschke TF: Dose-dependent inhibition of cyclosporine metabolism in mice by fluconazole. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 68:89-93, 1990
99. Ford GA, Hoffman BB, Blaschke TF: Effect of temazepam on blood pressure regulation in healthy elderly subjects. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 29:61-67, 1990
100. Cohen P, Collart L, Prober CG, Fischer AF, Blaschke TF: Gentamicin pharmacokinetics in neonates undergoing extracorporeal membrane oxygenation. THE PEDIATRIC INFECTIOUS DISEASES JOURNAL 9:562-566, 1990
101. Skinner MH, Matano R, Hazle W, Blaschke TF: Acetaminophen metabolism in recovering alcoholics. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 12:513-515, 1990
102. Espiritu-Quiza FA, Skinner MH, Blaschke TF: Ranitidine alters antipyrine metabolism in mice. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 12:631-635, 1990
103. Lenert LA, Lurie J, Coleman R, Klostermann H, Blaschke T: Aminoglycoside Therapy Manager: an advanced computer program for decision support for drug dosing and therapeutic monitoring. PROCEEDINGS - 14TH ANNUAL SYMPOSIUM ON COMPUTER APPLICATIONS IN MEDICAL CARE, (Miller, R ed.), Institute of Electrical and Electronics Engineers, New York, 1990, pp. 982-983
104. Leemann TD, Blaschke TF: Semiquantitative simulation for reasoning about physiological models of drug kinetics and effects. SCHWEIZ MED WOCHENSCHRIFT (SWITZERLAND) 120:1849-1852, 1990
105. Ford GA, Katzir D, Blaschke TF, Hoffman BB: Responsiveness of peripheral veins to

vasodilators and the effect of nifedipine on α -adrenergic responsiveness in hypertension. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 50:192-198, 1991

106. Vincent J, Blaschke TF, Hoffman BB: Desensitization of β -adrenergic and PGE1 receptor-mediated human vascular smooth muscle relaxation. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 19:447-452, 1992.
107. Ng M, Arias AA, Blaschke TF, Zare RN: Analysis of free intracellular nucleotides using high performance capillary electrophoresis. *ANALYTICAL CHEMISTRY* 64:1682-1684, 1992.
108. Ford GA, Hoffman BB, Blaschke TF: Beta adrenergically mediated cardiac chronotropic and vascular smooth muscle responses during propranolol therapy and withdrawal in young and elderly persons. *JOURNAL OF GERONTOLOGY: MEDICAL SCIENCES* 47:M22-26, 1992.
109. Ford GA, Hoffman BB, Vestal RE, Blaschke TF: Age-related changes in adenosine and beta-adrenergic responsiveness of vascular smooth muscle in man. *BRITISH JOURNAL OF CLINICAL PHARMACOLOGY* 33:83-87, 1992.
110. Vincent J, Blaschke TF, Hoffman BB: Vascular reactivity to phenylephrine and angiotensin II: comparison of direct venous and systemic vascular responses. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 51:68-75, 1992.
111. Jaruratanasirikul S, Cooper AD, Blaschke TF: Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-OH debrisoquin or other metabolites of debrisoquin. *DRUG METABOLISM AND DISPOSITION* 20:379-382, 1992.
112. Eichler HG, Blaschke TF, Kraemer FG, Ford GA, Blochl-Daum B, Hoffman BB: Responsiveness of superficial hand veins to alpha-adrenergic agonists in insulin-dependent diabetic patients. *CLINICAL SCIENCE* 82:163-168, 1992
113. Lenert LA, Lurie J, Sheiner LB, Coleman R, Klostermann H, Blaschke TF: Advanced computer programs for drug dosing that combine pharmacokinetic and symbolic modeling of patients. *COMPUTERS AND BIOMEDICAL RESEARCH* 25:29-42, 1992.
114. Skinner MH, Futterman A, Morrisette D, Thompson L, Hoffman BB, Blaschke TF: Atenolol compared with nifedipine: effect on cognitive function and mood in elderly hypertensive patients. *ANNALS OF INTERNAL MEDICINE* 116:615-623, 1992.
115. Dachman WD, Ford GA, Hoffman BB, Blaschke TF: Bradykinin-induced venodilation is not impaired with aging in humans. *JOURNAL OF GERONTOLOGY: MEDICAL SCIENCES* 47:M166-170, 1992.
116. Lenert LA, Klostermann H, Coleman RW, Lurie J, Blaschke TF: Practical computer-assisted dosing for aminoglycoside antibiotics. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY* 36:1230-1235, 1992.
117. Vincent JV, Dachman WA, Blaschke TF, Hoffman BB: Pharmacological tolerance to alpha₁-adrenergic receptor antagonism mediated by terazosin in humans. *JOURNAL OF CLINICAL INVESTIGATION* 90:1763-1768, 1992.
118. Haefeli WE, Gumbleton M, Benet LZ, Hoffman BB, Blaschke TF: Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 52:590-596, 1992.
119. Vincent J, Kongpatanakul S, Blaschke TF, Hoffman BB: Desensitization of nitrate-induced venodilation: reversal with oral N-acetylcysteine in humans. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 20:907-912, 1992.

120. Collart L, Blaschke TF, Boucher F, Prober C: Potential of population pharmacokinetic modelling to limit the frequency of blood sampling while optimizing the estimates of pharmacokinetic parameters. *DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS* 18:71-80, 1992.
121. Dachman WD, Ford GA, Blaschke TF, Hoffman BB: Mechanism of bradykinin-induced venodilation in humans. *JOURNAL OF CARDIOVASCULAR PHARMACOLOGY* 21:241-248, 1993.
122. Haefeli WE, Bargetzi MJ, Starnes HF, Blaschke TF, Hoffman BB: Evidence for activation of the sympathetic nervous system by recombinant human interleukin-1 β in humans. *JOURNAL OF IMMUNOTHERAPY* 13:136-140, 1993.
123. Mole L, Israelski D, Bulp J, O'Hanley P, Merigan T, Blaschke T: The pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES* 6:56-60, 1993.
124. Lenert LA, Markowitz DR, Blaschke TF: Primum Non Nocere? Valuing of the risk of drug toxicity in therapeutic decision-making. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 53:285-291, 1993
125. Ford GA, Blaschke TF, Wiswell R, Hoffman BB: Effect of aging on changes in plasma potassium during exercise. *JOURNAL OF GERONTOLOGY: MEDICAL SCIENCES* 48:M140-M145, 1993
126. Haefeli WE, Srivastava N, Kongpatanakul S, Blaschke TF, Hoffman BB: Lack of role of endothelium-derived relaxing factor in effects of α -adrenergic agonists in cutaneous veins in humans. *AMERICAN JOURNAL OF PHYSIOLOGY* 264 (*Heart and Circulatory Physiology* 33): H364-H369, 1993.
127. Haefeli WE, Srivastava N, Kelsey KT, Weincke JK, Hoffman BB, Blaschke TF: Glutathione S-transferase μ polymorphism does not modify the venodilatory potency of nitroglycerin in human veins. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 53:463-468, 1993.
128. Dachman WD, Varallo-Bedarida G, Blaschke TF, Hoffman BB: Histamine-induced venodilation in human beings involves both H₁ and H₂ receptor subtypes. *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY* 93:606-614, 1994.
129. Bedarida GV, Bushell E, Haefeli WE, Blaschke TF, Hoffman BB: Responsiveness to bradykinin in veins of hypercholesterolemic humans *CIRCULATION* 88:2754-2761, 1993.
130. Bedarida GV, Kim D, Blaschke TF, Hoffman BB: Venodilation in Raynaud's disease. *LANCET* 342:1451-1454, 1993.
131. Sale ME, Sheiner LB, Volberding P, Blaschke TF: Zidovudine response relationships in early HIV infection. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 54:556-566, 1993
132. Bedarida GV, Kim D, Blaschke TF, Hoffman BB: Characterization of an inhibitor of nitric oxide synthase in human-hand veins. *HORMONE AND METABOLIC RESEARCH* 26:109-112, 1994.
133. Bedarida GV, Bushell E, Blaschke TF, Hoffman BB: Differential regulation of H₁ and H₂ histamine receptor-mediated vasodilation with aging in humans. *CLINICAL PHARMACOLOGY AND THERAPEUTICS* 58:73-80, 1995
134. Ford GA, Dachman WD, Blaschke TF, Hoffman BB: Effect of aging on β_2 -adrenergic receptor-stimulated flux of K⁺, PO₄⁻, FFA and glycerol in human forearms. *JOURNAL OF APPLIED PHYSIOLOGY* 78:172-178, 1995.
135. Jacobs C, Moreno B, Blaschke T: A multimodality approach to Preparation for Clinical

Medicine. ACADEMIC MEDICINE 70:99-100, 1995

136. Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG: A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. CANCER 75:1354-1359, 1995.
137. Kastrissios H, Chao NJ, Blaschke TF: Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. CANCER CHEMOTHERAPY AND PHARMACOLOGY 38:425-430, 1996.
138. Kastrissios H, Flowers NT, Blaschke TF: Introducing medical students to medication noncompliance. CLINICAL PHARMACOLOGY AND THERAPEUTICS 59:577-582, 1996.
139. Kastrissios H, Nakano M, Burton P, Blaschke TF: Improved combined solid-phase extraction-RIA method for quantifying zalcitabine in plasma. CLINICAL CHEMISTRY 42:465-66, 1996.
140. Girard P, Sheiner LB, Kastrissios H, Blaschke TF: Do we need full electronic compliance data for population pharmacokinetic analysis? JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 24:265-282, 1996
141. Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari F, Collier A, et al.: Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG184 Protocol Team. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 12:363-70, 1996
142. Grossmann M, Abiose A, Tangphao O, Blaschke TF, Hoffman BB: Morphine-induced venodilation in humans. CLINICAL PHARMACOLOGY AND THERAPEUTICS 60:554-560, 1996.
143. Gopalakrishnan V, Burton PJ, Blaschke TF: A high-performance liquid chromatographic assay for the quantitation of L-arginine in human plasma. ANALYTICAL CHEMISTRY 68:3520-23, 1996
144. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC, Blaschke TF, Simpson D, McLaren C, Rooney J, Salgo M: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts between 200 and 500 per cubic millimeter. NEW ENGLAND JOURNAL OF MEDICINE 335:1081-90, 1996
145. Vanhove GF, Schapiro JM, Winters MA, Merigan TC, Blaschke TF: Compliance and drug failure in protease inhibitor monotherapy. JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 276:1955-56, 1996 [Letter]
146. Abiose AK, Grossmann M, Tangphao O, Hoffman BB, Blaschke TF: Chloroquine-induced venodilation in human hand veins. CLINICAL PHARMACOLOGY AND THERAPEUTICS 61:677-83, 1997.
147. Vanhove GF, Kastrissios H, Gries J-M, Verotta D, Park K, Collier AC, Squires K, Sheiner LB, Blaschke TF: Pharmacokinetics of saquinavir, zidovudine and zalcitabine in combination therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41:2428-32, 1997.
148. Vanhove GF, Gries J-M, Verotta D, Sheiner LB, Coombs R, Collier AC, Blaschke TF: Exposure-response relationships for saquinavir, zidovudine and zalcitabine in combination therapy. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41:2433-38, 1997.
149. Park K, Verotta D, Blaschke TF, Sheiner LB: A semiparametric method for describing noisy population pharmacokinetic data. JOURNAL OF PHARMACOKINETICS AND

150. Moreno H, Urae A; Tangphao O, Chalon S, Abiose AK, Hoffman BB, and Blaschke TF. Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. AMERICAN JOURNAL OF PHYSIOLOGY 275(3 Pt 2):H1040-H1045, 1998.
151. Kastrissios H, Suárez J-R, Katzenstein D, Girard P, Sheiner LB, Blaschke TF: Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS 12:2295-2303, 1998.
152. Kastrissios H, Suárez JR, Hammer S, Katzenstein D, Blaschke TF: The extent of noncompliance in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS 12:2305-2311, 1998.
153. Girard P, Blaschke TF, Kastrissios H, Sheiner LB: A Markov mixed effect regression model for drug compliance. STATISTICS IN MEDICINE 17:2313-2333, 1998
154. Chalon S, Moreno H, Hoffman BB, Blaschke TF: Angiotensin converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers. CLINICAL PHARMACOLOGY AND THERAPEUTICS 65:295-303, 1999.
155. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. CIRCULATION 98:1842-1847, 1998
156. Chalon S, Tejura B, Moreno H, Urae A, Blaschke TF, Hoffman BB: Role of nitric oxide in isoprenaline and sodium nitroprusside-induced relaxation in human hand veins. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 47: 91-98, 1999
157. Washington CB, Duran GE, Man M, Sikic BI, Blaschke TF. Interaction of the anti-HIV Protease Inhibitors with the Multidrug Transporter, P-glycoprotein (P-gp) in Human Cultured Cells. JOURNAL OF AIDS AND HUMAN RETROVIROLOGY 19:203-9, 1998
158. Chalon S, Bedarida G, Moreno H, Tejura B, Urae A, Hoffman BB and Blaschke TF. Inhibition of angiotensin-converting enzyme in human hand veins. CLINICAL PHARMACOLOGY AND THERAPEUTICS 65: 58-65, 1999.
159. Tangphao O, Chalon S, Coulston AM, Moreno H, Chan JR, Cooke JP, Hoffman BB, Blaschke TF: L-arginine and nitric oxide-related compounds in plasma : comparison of normal and arginine-free diets in a 24-h crossover study. VASCULAR MEDICINE 4: 27-32, 1999.
160. Tangphao O, Chalon S, Moreno H, Hoffman BB and Blaschke TF. Pharmacokinetics of L-arginine during chronic administration to hypercholesterolemic patients. CLINICAL SCIENCE 96:199-207, 1999.
161. Tangphao O, Grossmann M, Chalon S, Hoffman BB, and Blaschke TF. Pharmacokinetics of intravenous and oral l-arginine in normal volunteers. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY 47:261-6, 1999.
162. Tangphao O, Chalon S, Moreno H, Abiose AK, Blaschke TF, and Hoffman BB. Heparin-induced Vasodilation in Human Hand Veins. CLINICAL PHARMACOLOGY AND THERAPEUTICS 66:232-8, 1999.
163. Chan JR, Böger RH, Bode-Böger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP: Asymmetric Dimethylarginine Increases Mononuclear Cell Adhesiveness in Hypercholesterolemic Humans ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2000 Apr;20(4):1040-6.
164. Chalon S, Moreno H, Benowitz NL, Hoffman BB, Blaschke TF. Nicotine Impairs Endothelium-dependent Dilatation in Human Veins in Vivo. CLINICAL

PHARMACOLOGY AND THERAPEUTICS 67:391-7, 2000.

165. Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. DRUG METABOLISM AND DISPOSITION. 28(3):329-34, 2000.
166. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF: The Disposition of Saquinavir in Normal and P-glycoprotein Deficient Mice, Rats and in Cultured Cells. DRUG METABOLISM AND DISPOSITION. 28(9):1058-1062, 2000.
167. Duchna HW, Guilleminault C, Stoohs, RA, Moreno H, Hoffman BB, Blaschke TF: Vascular Reactivity in Obstructive Sleep Apnea Syndrome. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 161:187-191, 2000.
168. Fichtenbaum CJ, Gerber J, Rosenkranz S, Segal Y, Aberg J, Blaschke T, Alston B, Fang F, Kozel B, Aweeka F. Pharmacokinetic Interactions Between Protease Inhibitors And Statins in HIV Seronegative Volunteers: ACTG Study A5047. AIDS 16:569-577, 2002
169. Herforth C, Stone JA, Jayewardene AL, Blaschke TF, Fang F, Aweeka FT: Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectroscopy: important factors for method optimization. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 15:185-195, 2002
170. Washington CB, Flexner C, Sheiner LB, Rosenkranz SL, Segal Y, Aberg JA, Blaschke TF and the ACTG 378 Study Team: The Effect of Simultaneous versus Staggered Dosing on the Pharmacokinetic Interactions between Paired Combinations of Nelfinavir, Ritonavir and the Soft Gelatin Capsule of Saquinavir. (Submitted for Publication)
171. Lu J-F, Blaschke TF, Flexner C, Rosenkranz SL, Sheiner LB, and AIDS Clinical Trials Group Protocol 378 Investigators: Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir and Saquinavir After Simultaneous and Staggered oral administration. (Submitted for Publication)
172. Abiose AK, Lu H, Hoffman BB, Blaschke TF: Magnesium-induced venodilation in humans: independent of nitric oxide release. (Submitted)
173. Abiose AK, Lafayette R, Moreno H, Blaschke TF, Hoffman BB: Increased sensitivity of venoconstriction mediated by the α -adrenergic agonist phenylephrine in patients with renal failure. (Submitted)

APPEARS THIS WAY
ON ORIGINAL

REVIEWS, BOOK CHAPTERS, EDITORIALS, PROCEEDINGS:

1. Berk PD, Blaschke TF and Rodkey FL: "Effects of phenobarbital and glutethimide on heme turnover and hepatic bilirubin clearance in man" in the Liver: Quantitative Aspects of Structure and Function (Paumgartner G and Preisig R, eds.), S. Karger, Basle, 1973.
2. Blaschke TF and Melmon KL: Clinical importance of the pharmacologic effects of radiopaque dyes. RAT DRUG THER 7: Number 10, October 1973.
3. Berk PD, Martin JF, Blaschke TF, Scharschmidt BF and Plotz PH: Unconjugated hyperbilirubinemia: Physiologic evaluation and experimental approaches to therapy. (NIH Conference) ANN INT MED 82:552-570, 1975.
4. Blaschke TF, Berk PD, Scharschmidt BF, Waggoner JG and Berlin NI: "New approach to the estimation of early labelled peak bilirubin synthesis in man." Chapter 18 in Chemistry and Physiology of Bile Pigments, Proceedings of an international symposium (Berk PD and Berlin NI, eds.), DHEW Publication No. (NIH) 77-1100 Washington, D.C., 1977, pp 206-215.
5. Berk PD, Blaschke TF and Gisselbrecht C: "Discrepancy between drug effects on early labelling and bilirubin production." Chapter 22 in Chemistry and Physiology of Bile Pigments, Proceedings of an international symposium (Berk PD and Berlin NI, eds.), DHEW Publication No. (NIH) 77-1100 Washington, D.C., 1977, pp.254-262.
6. Rowland M, Blaschke TF, Meffin PJ and Williams RL: "Pharmacokinetics in disease states modifying hepatic and metabolic function" in The Effect of Disease States on Drug Pharmacokinetics (Benet LZ, ed.), American Pharmaceutical Association, Academy of Pharmaceutical Sciences, Washington, D.C., 1976, pp. 53-75.
7. Blaschke TF: Protein binding and kinetics of acidic drugs in liver disease. CLINICAL PHARMACOKINETICS 2:32-44, 1977.
8. Blaschke TF and Rubin PC: Hepatic first pass metabolism in liver disease. CLINICAL PHARMACOKINETICS 4:423-432, 1979.
9. Blaschke TF and Melmon KL: "Antihypertensive agents and the drug therapy of hypertension." Chapter 32 in The Pharmacological Basis of Therapeutics (Goodman LS and Gilman A, eds.), VI edition, Macmillan, New York, 1980, pp. 793-818.
10. Bjornsson TD, Meffin PJ, Swezey SE and Blaschke TF: "Disposition and turnover of vitamin K1 in man" in Vitamin K Metabolism and Vitamin K-dependent Proteins (Suttie JW, ed.), University Park Press, Baltimore, 1980, pp. 328-332.
11. Blaschke TF: "Potential drug interactions in aging patients." Chapter 7 in Age and the Pharmacology of Psychoactive Drugs (Raskin A, Robinson DS and Levin J, eds.), Elsevier North Holland, New York, 1981, pp. 93-103.
12. Blaschke TF, Cohen SN, Tatro DS and Rubin PC: "Drug-drug interactions and aging" in Clinical Pharmacology and the Aged Patient (Aging, volume 16) (Jarvik LF, Greenblatt DJ and Harmon D, eds.), Raven Press, New York, 1981, pp.11-26.
13. Blaschke TF "Dosage modification in patients with hepatic dysfunction" in Advances in Pharmacology and Therapeutics II, Vol 6 Clinical Pharmacology, Teaching in Pharmacology (Yoshida H, Hagihara Y, and Ebashi S, eds.), Pergamon Press, Oxford and New York 1982, pp. 167-176.
14. Melmon KL and Blaschke TF: The under-educated physician's therapeutic decisions. NEW ENGLAND JOURNAL OF MEDICINE 308:1473-1474, 1983.
15. Giacomini KM and Blaschke TF: The effect of concentration-dependent binding on the pharmacokinetics and pharmacodynamics of disopyramide. CLINICAL PHARMACO-

KINETICS 9(Suppl. 1):42-48, 1984.

16. Pan HY and Blaschke TF: Computer data banks in medicine. INTERNAL MEDICINE FOR THE SPECIALIST 6(5):147-159, May 1985.
17. Glazener FS and Blaschke TF: Adverse interaction of digoxin, metoprolol and diltiazem. HOSPITAL PHYSICIAN 20:52-62, February, 1984 and PRIMARY CARDIOLOGY 10:96-106, February, 1984.
18. Schulz P, Dick P, Blaschke TF and Hollister LE: Discrepancies between pharmacokinetic studies of amitriptyline. CLIN PHARMACOKIN 10:257-268, 1985.
19. Blaschke TF, Nies AS and Mamelok RD: "Principles of Therapeutics", Chapter 3 in The Pharmacological Basis of Therapeutics, Seventh Edition, (Gilman AG, Goodman LS, Rall TW and Murad F, eds), MacMillan Publishing Company, New York, 1985, pp. 49-65.
20. Rudd P and Blaschke TF: "Antihypertensive Agents and the Drug Therapy of Hypertension", Chapter 32 in The Pharmacological Basis of Therapeutics, Seventh Edition, (Gilman AG, Goodman LS, Rall TW and Murad F, eds), MacMillan Publishing Company, New York, 1985, pp. 784-805.
21. Gray JD and Blaschke TF: Fever: To treat or not to treat. RATIONAL DRUG THERAPY, 19(12):1-6, December, 1985.
22. Blaschke TF and Pan HY-M: "Modification of Drug Binding and Pharmacokinetics in Acute Myocardial Infarction" in Protein Binding and Drug Transport, (Tillement JP and Lindenlaub E, eds) Symposia Medica Hoechst 20, FK Schattner Verlag, Stuttgart, New York, 1986, pp. 353-369.
23. Bressler R, Blaschke TF, Nies AS, Sheiner LB: "Clinical Pharmacology". In MKSAP VII, pp 563-577 (Syllabus) pp 641-647 (Multiple Choice Questions) and pp 51-61 (Answers, Critiques, References), American College of Physicians, Philadelphia, 1985, 1986.
24. Blaschke TF: "Pharmacokinetics and Pharmacoeconomics" Section VI in Current Topics in Medicine, Scientific American Medicine, Scientific American Inc., New York pp:CTM VI-1 to CTM VI-12, 1986.
25. Blaschke, TF and Giacomini, KM: "Pharmacodynamic Consequences of Enantio-selective Drug Disposition." In Pharmacology. Proceedings of the Xth International Congress of Pharmacology (IUPHAR), Sydney, 23-28 August 1987 (Rand M.J. and Raper C. editors) Elsevier Science Publishers B.V., Amsterdam, pp 803-806, 1987.
26. Blaschke T, Benowitz N, Brater DC, Hoffman BB: "Clinical Pharmacology". In MKSAP VIII, Part A, Book 2, pp 57-80 (Syllabus, Multiple Choice Questions) and Part A, Book 7, pp 293-303 (Answers, Critiques, and Bibliographies), American College of Physicians, Philadelphia, 1988.
27. Katzir D, and Blaschke TF: The cyclosporine-ketoconazole interaction. HOSPITAL THERAPY 15 (1):99-112, January 1990.
28. Kondo J-JL, Blaschke TF: Drug-drug interactions in geriatric patients. In Gerontology. 4th International Symposium. Present State and Research Perspectives in the Experimental and Clinical Gerontology. (Platt D., ed.) Springer-Verlag, Berlin Heidelberg, pp 257-269, 1989.
29. Blaschke, TF: Clinical pharmacology comes of age. CLINICAL PHARMACOLOGY AND THERAPEUTICS 46:485-488, 1989.
30. Blaschke TF: Research and the American Society for Clinical Pharmacology and Therapeutics. CLINICAL PHARMACOLOGY AND THERAPEUTICS 47(2,Suppl.):20-22, 1990.

31. Blaschke TF: Hospital information systems and the quality of therapeutics. *METHODS OF INFORMATION IN MEDICINE* 29:163-166, 1990.
32. Sale ME, Blaschke TF: Incorporating pharmacokinetic/pharmacodynamic modeling in drug development - are we ready? *DRUG INFORMATION JOURNAL* 26:119-124, 1992.
33. Blaschke TF: Prescriptions. Chapter 33 in Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics, Third Edition (Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW, eds.), McGraw-Hill, Inc., New York, 1992, pp 895-910.
34. Skinner MH, Blaschke TF: Clinical Pharmacokinetics of Rifabutin. *CLINICAL PHARMACOKINETICS* 28(2):115-125, 1995.
35. Blaschke TF, Skinner MH: The Clinical Pharmacokinetics of Rifabutin. *CLINICAL INFECTIOUS DISEASES* 22(Suppl 1):S15-22, 1996.
36. Nakano M, Reynoso P, Blaschke TF: Intra- and inter-individual variability of zidovudine phosphorylation in human peripheral blood mononuclear cells. Proceedings of the 16th Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, Meiji Kinenkan, Tokyo, November 1-2, 1995. In "Rinshou-Yakuri" *JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS* 27:33-34, 1996 (in Japanese)
37. Kastrissios H, Blaschke TF: Medication compliance as a feature in drug development. *ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY* 37:451-75, 1997.
38. Urquhart J, Blaschke TF: Patient compliance with anti-HIV treatments. *PRACTICAL ISSUES IN HIV AND AIDS PATIENT MANAGEMENT*, 1997, Issue Number 7 (August 1997), published by Van Zuiden Communications B.V., Alphen aan de Rijn, The Netherlands.
39. Ford GA, Hoffman BB, Blaschke TF: Pharmacodynamics. Chapter 5 in Drug Therapy in Old Age (George CF, Woodhouse KW, Denham MJ, and MacLennan WJ, eds.), John Wiley and Sons, Ltd., London, 1998, pp. 59-72.
40. Kastrissios H, Blaschke TF: Therapeutic Implications of Nonadherence with Antiretroviral drug regimens. *HIV: ADVANCES IN RESEARCH AND THERAPY* 8(2):24-28, November, 1998.
41. Blaschke TF: Writing Prescriptions. Chapter 26 in Melmon and Morrelli's Clinical Pharmacology: Basic Principles in Therapeutics, Fourth Edition (Carruthers SG, Hoffman BB, Melmon KL, Nierenberg DW, eds.), McGraw-Hill, Inc., New York, 2000, pp. 1267-88.
- 42a. Lesko LJ, Rowland M, Peck CC, Blaschke TF; Optimizing the Science of Drug Development: opportunities for better candidate selection and accelerated evaluation in humans [Conference Report]. *JOURNAL OF CLINICAL PHARMACOLOGY* 40(8):803-14, 2000.
- 42b. Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. *EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES* 10(4):iv-xiv, 2000.
- 42c. Lesko LJ, Rowland M, Peck CC, Blaschke TF; Optimizing the Science of Drug Development: opportunities for better candidate selection and accelerated evaluation in humans. *PHARMACEUTICAL RESEARCH* 17(11):1335-44, 2000.
43. Blaschke TF: PIs as Pharmacoenhancers - Modulating and monitoring drug exposure [Editorial Comment]. *THE AIDS READER* 11(2):96-7, 2001

44. Blaschke TF: Effect of Liver Disease on Dose Optimization. In Optimal Dose Identification, Proceedings of the Esteve Foundation Symposium IX. (Breckenridge A, ed.) International Congress Series 1220 Elsevier Science BV, Amsterdam, 2001, pp. 247-258.

APPEARS THIS WAY
ON ORIGINAL